Drug Profile
MK 5160
Alternative Names: MK5160Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antihyperglycaemics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC)
- 28 May 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (SC)
- 30 Jan 2018 Merck Sharp & Dohme completes the MK-5160-002 phase I trial for Type-1 diabetes mellitus and Type-2 diabetes mellitus in USA (NCT03095651)